Author:
Ufondu Wisdom,Robinson Christopher L.,Hussain Nasir,D’Souza Ryan S.,Karri Jay,Emerick Trent,Orhurhu Vwaire J.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. GBD. Low Back Pain Collaborators (2023) Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2021;5:e316–29. https://doi.org/10.1016/S2665-9913(23)00098-X. Describes the issue of lower back pain as an epidemic and provides relevant statistics.
2. Atluri S, Murphy MB, Dragella R, et al. Evaluation of the Effectiveness of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Chronic Low Back Pain Due to Severe Lumbar Spinal Degeneration: A 12-Month, Open-Label, Prospective Controlled Trial. Pain Physician. 2022;25:193–207. Significant positive analgesic outcome with MSCs.
3. Remotti E, Nduaguba C, Woolley PA, et al. Review: Discogenic Back Pain: Update on Treatment. Orthop Rev (Pavia). 2023;15:84649. https://doi.org/10.52965/001c.84649.
4. Fatoye F, Gebrye T, Ryan CG, et al. Global and regional estimates of clinical and economic burden of low back pain in high-income countries: a systematic review and meta-analysis. Front Public Health. 2023;11:1098100. https://doi.org/10.3389/fpubh.2023.1098100.
5. Atkinson JH, Slater MA, Capparelli EV, et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain. 2016;157:1499–507. https://doi.org/10.1097/j.pain.0000000000000554.